reason report
price chang estim chang analysi
increas price target per
reiter invest rate increas former
price target per share follow
compani report oper result remain
challeng result pandem view set
exit calendar year favor core fundament
expect improv prior year comp favor
respiratori franchis revenu stand benefit
crisi deep discount rel valuat
alreadi reflect known headwind
increas price increas former
price target establish height crisi
multipl ev/revenu ev/ebitda
non-gaap earn versu former price target
assum multipl ev/ebitda ev/
revenu non-gaap earn
guidanc updat expect withdrew compani
oper guidanc due pandem
chang estim base on-going uncertainti
associ pandem reduc
revenu non-gaap earn estim million
per share respect likewis former
estim also fine-tun million
million per share earn
estim revis summar tabl left
rel valuat summari share current trade
revenu ebitda
trade like multipl respect
alpharetta
georgia spun tax-
free spin effect novemb may
divestitur legaci ip franchis
transform pure play medic devic
concern industry-lead share within market
surgic chronic pain respiratori
digest health compani plan util exist
import disclosur analyst certif page report access current disclosur stephen
capac pursu growth acquisit
inc cover compani client may refer
oper summari avnss quarterli sale increas million pre-cal consensu
million specif oper period neom summit contribut growth compani
benefit strong demand chronic segment grew million driven neom
respiratori product relat coronaviru pain manag sale grew million coolief
grew excess first two month oper period neg impact
pandem addit total revenu partial off-set unfavor price product mix
adjust gross margin pre-cal consensu declin year year due unfavor product
mix rel higher distribut cost compani report adjust oper profit million
adjust ebitda million result compani report non-gaap earn per share pre-cal
strateg updat confid compani exist cash posit suffici navig
relat headwind expect exit least million cash bearish
scenario specif reduc plan capit expenditur cut discretionari spend
suspend merit relat salari increas furthermor compani liquid posit stand benefit
certain opportun relat care act initi addit compani previous announc
step save million cost howev longer anticip compani
gener posit free cash flow year addit new system implement continu
versu prior assumpt complet
balanc sheet review oper period compani util million oper cash flow
alloc million capit expenditur result million free cash flow result compani
exit quarter million cash cash equival million debt equival
net debt per dilut share
histor project financi
remain share enter set appear favor easi er comp improv fundament cost
exiti ng discount relati valuat alreadi reflect known headwind
ex coolief track plan growth
respiratori franchis enjoy tailwind like cye
comp easier share trade notabl rel discount peer
weigh higher margin pain manag growth outlook
variou integr relat cost remain
histor project financi
on-q suppli issu still resolv
ex core busi grow low single-digit
close stock price may
note million except per share data
compani document stephen inc estim
thousand except per share data
good sold
research develop
sell gener
incom tax
cc organ growth acquisit contribut
respiratori sale benefit due
gross margin pressur increas ship cost
opex in-lin expect
note million except per share data
compani document stephen inc estim
note million except per share data
compani document stephen inc estim
note million except per share data
compani document stephen inc estim
fiscal period
fiscal period
fiscal period
consolid statement incom adjust
period
dollar million except per share data
product sold
reasearch develop
sell gener expens
provis incom tax
incom continu oper
incom discontinu oper net tax
margin analysi revenu
reasearch develop
sell gener expens
reasearch develop
sell gener expens
compani report stephen inc estim
list figur page
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
